BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo® (cemiplimab-rwlc) to treat patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression.

First patient dosed at the Emory University School of Medicine in Atlanta, Georgia Trial will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in up to 200 patients hospitalized with COVID-19 ’

IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy IMV to host a combined conference call and webcast on November 12, 2020 at 8:00am ET The webcast will begin with a poster presentation by Dr. Neil Berinstein, Principal Investigator of the SpiReL study, and a discussion about the biomarkers associated with clinical response

FASENRA ® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial 62% of patients stopped OCS use in largest ever steroid sparing trial in severe asthma

Supported by a strong U.S. and Chinese investor syndicate including Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners and CMG-SDIC Capital Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open of U.S. financial markets on Thursday, November 5, 2020. Kura’s management will host a webcast and conference call at 8 a.m. ET / 5 a.m. PT that day to discuss the financial results and provide a corporate

Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12% Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis

Insignis Therapeutics (“Insignis”), a biotech company focused on developing innovative therapeutics for anaphylaxis treatment and HLK Pharmacin, a global drug development company, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that the Company will be hosting a Key Opinion Leader (KOL) call with Dr. Mark Burgmans, an Interventional Radiologist at the Leiden University Medical Center (LUMC) in The Netherlands, on Thursday, November 5, 2020, at 11:30am ET. Dr. Mark Burgmans will discuss results from a prospective ph

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2020 financial results after market close on Thursday, November 5 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to di